TMCnet News
Monarch Medical Technologies and Voluntis to Host Webinar on Use of Technology to Support Inpatient and Outpatient Insulin ManagementDespite advances in treatment and clear guidelines, many patients with diabetes are failing to achieve target glucose levels both in the inpatient and outpatient setting. One of the main challenges posing a barrier is clinical inertia preventing the initiation and intensification of insulin therapy. Insulin therapy has been proven to significantly reduce hemoglobin A1c levels in individuals with diabetes and better manage hyperglycemia, yet countless studies show that insulin initiation and intensification is frequently and inappropriately delayed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005540/en/ Monarch and Voluntis, who formed a business relationship last year, are partnering to offer a complimentary webinar, "How Technology Can Support Adoption of Best Practices for Inpatient and Outpatient Insulin Management." The webinar will discuss the current challenges in initiating and managing insulin therapy, review the recommended practices in both the inpatient and outpatient setting, and discuss how technology can be used and implemented to benefit both patients and providers. You may register for the webinar here. When Tuesday, June 25, 2019 at 12:00 pm EST Speakers Amy Butts PA-C, MPAS, CDE, BC-ADM, Endocrine Physician Assistant, Wheeling Hospital Mark Vanderwel, MD, Medical Director of the Pediatric Endocrinology Division, Atrium Health Learning Objectives
Following the live webinar, a recording will be available to download on monarchmedtech.com within 24 hours of the live event. About Monarch Medical Technologies Monarch Medical Technologies is the leading provider of electronic systems for inpatient glycemic management. Monarch's EndoTool® Glucose Management System offers personalized dosing recommendations for intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared, patented software suite, EndoTool has been chosen by more than 300 hospitals to provide unsurpassed patient-specific glycemic control across a broad population of patients, and ultimately deliver better, safer care. For more information, please visit monarchmedtech.com. About Voluntis
Voluntis creates digital therapeutics that empower people suffering from
chronic conditions to self- manage their treatment every day, thus
improving real-world outcomes. Combining mobile and web apps, Voluntis'
solutions deliver personalized recommendations to the patient and the
care team so that they can, for example, adjust treatment dosage, manage
side effects or monitor symptoms. These real- time recommendations are
based on digitized clinical algorithms. Leveraging its Theraxium
technology platform, Voluntis has designed and operates multiple digital
therapeutics, especially in diabetes and oncology. Voluntis has
long-standing partnerships with leading life science companies such as
Abbvie, AstraZeneca, Roche, Sanofi and Onduo. Based out of Boston and
Paris, France, Voluntis is a founding member of the Digital Therapeutics
Alliance. For further information: http://www.voluntis.com. Diabeo® is a registered trademark of Sanofi. Insulia® is a registered trademark of Voluntis. For further information: http://www.voluntis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190617005540/en/ |